Last updated 2026-06-18
- Went public, Aug 2015
- Raised $20.6M funding round, Sep 2024
- Raised $16M funding round, Mar 2024
Total raised
$69.5M
Last: 2024-09
Stage
Public
Founded
2011
Headcount
67
HQ
Rehovot, Israel
Sector
Health Tech & Life Sciences
About
Beyond Air is harnessing nitric oxide's pulmonary, antimicrobial, anti-inflammatory, and immunomodulatory mechanisms of action to deliver global access to more treatment options from hospital to home.
Its revolutionary LungFit technology platform generates nitric oxide (NO) on-demand from ambient air and safely delivers it to patients to treat a variety of lung diseases. The LungFit PH is the first and only FDA approved system with patented Ionizer technology that generates nitric oxide using room air, enabling the delivery of unlimited, on-demand nitric oxide regardless of dose or flow.
Funding history · 4 rounds · $69.5M total
2024-09
$20.6M
2024-03
$16.0M
2023-06
$17.5M
2012-12
$1.3M
Q&A
- What was Beyond Air's most recent funding round?
- Beyond Air secured $20,600,000 in a funding round in September 2024.
- What was the amount and lead investor of Beyond Air's June 2023 funding round?
- In June 2023, Beyond Air raised $17,500,000 with.
- When did Beyond Air become a public company and on which exchange?
- Beyond Air became public on NASDAQ in August 2015 through an IPO that raised $11,643,750.
- What is Beyond Air's primary product and its key feature?
- Beyond Air's primary product is the LungFit PH, an FDA-approved system that generates nitric oxide on-demand from ambient air for treating various lung diseases.
- What is Beyond Air's employee count range?
- Beyond Air has an employee count in the 51-200 range.
- What was a significant partnership Beyond Air entered into in September 2023?
- In September 2023, Beyond Air partnered with Getz Healthcare to commercialize the LungFit PH device in several Asia-Pacific countries, including Australia, New Zealand, and Thailand.
- What recent financial restructuring did Beyond Air undertake in September 2024?
- In September 2024, Beyond Air terminated its loan agreements with.
- What is Beyond Air's affiliate, Beyond Cancer, developing?
- Beyond Cancer, an affiliate of Beyond Air, is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, with positive first-in-human clinical data presented in November 2023.
Team · 2
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Target customers
Healthcare & Life SciencesHealthcareProvidersPatientsLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
medical-deviceschronic-diseaserespiratoryasthmainfectionpharmaceuticalspulmonaryinhalationchronic-patients
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | beyondair.net/ |
|---|---|
| linkedin.com/company/5256195 | |
| Crunchbase | crunchbase.com/organization/ait |
Identifiers & details
| Former names | Advanced Inhalation Therapies |
|---|---|
| Founded | 2011-5 |
| Employees (exact) | 67 |
| Offices | Garden City |
| Market cap | $5.8M |
| Status reason | Public on NASDAQ on Aug, 2015 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2015-08 | $11.6M | |||
| 2017-02 | $10.2M | |||
| 2018-02 | $9.8M |